Lyka Labs Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Lyka Labs Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $3.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Lyka Labs Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $3.4M Trade | TransData Nexus

Lyka Labs Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $3.4M Total Trade · DGFT Verified

Lyka Labs Limited is an Indian pharmaceutical exporter with a total trade value of $3.4M across 5 products in 5 therapeutic categories. Based on 104 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Vancomycin ($1.4M), Hydrocortisone ($1.1M), Amikacin ($550.0K).

Lyka Labs Limited — Export Portfolio & Destination Treemap

Lyka Labs Limited pharmaceutical export portfolio — 5 products across 5 therapeutic categories. Source: Indian Customs (DGFT).

Who is Lyka Labs Limited? — Company Overview & Market Position

Lyka Labs Limited, established on December 29, 1976, is a prominent Indian pharmaceutical company specializing in the development, manufacturing, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company is headquartered in Mumbai, Maharashtra, India, at Spencer Building, Ground Floor, 30 Forjett Street, Tardeo, Grant Road West, Mumbai 400036. The Corporate Identification Number (CIN) assigned to Lyka Labs Limited is L24230GJ1976PLC008738. As of the latest available data, the company employs approximately 499 individuals. Lyka Labs Limited is publicly listed on both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE), with the ticker symbol 500259 on BSE and LYKALABS on NSE. The company's official website is www.lykalabs.com.

What Does Lyka Labs Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Vancomycin$1.4M 2Hydrocortisone$1.1M

Product Portfolio — Top 5 by Export Value

Lyka Labs Limited exports 5 pharmaceutical products across 5 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Vancomycin	Antibiotics	$1.4M	36	1.5%	10
2	Hydrocortisone	Corticosteroids	$1.1M	34	1.7%	13
3	Amikacin	Advanced Antibiotics	$550.0K	11	2.6%	5
4	Amphotericin	Antifungals	$209.2K	20	0.2%	13
5	Levamisole	Antimalarial & Antiparasitic	$150.0K	3	5.6%	2

Lyka Labs Limited exports 5 pharmaceutical products across 5 therapeutic categories with a total export value of $3.4M. The top category is Antibiotics (40.4% of portfolio), followed by Corticosteroids (32.7%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Lyka Labs Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Lyka Labs Limited operates a WHO-GMP certified and ISO 9001:2000 certified manufacturing facility located in Ankleshwar, Gujarat, India. This facility specializes in the production of a diverse range of pharmaceutical formulations, including lyophilized injections, topical formulations such as creams, ointments, foams, gels, and lotions. The manufacturing plant is equipped with state-of-the-art infrastructure to ensure the consistent quality and reliability of its products.

3Key Leadership

The leadership team at Lyka Labs Limited comprises several key executives:

Kunal Narendra Gandhi: Managing Director, Chief Executive Officer, Promoter, and Director.

Yogesh Babulal Shah: Chief Financial Officer and Executive Director.

Shailendra Kumar Agrawal CS: Company Secretary and Compliance Officer.

Babulal Jain: Independent Director.

Prashant Premchand Godha: Non-Executive Director.

Shashil Philip Mendonsa: Non-Executive Director.

Neeraj Golas: Independent Director.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Lyka Labs Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Lyka Labs Limited has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Ankleshwar, Gujarat, holds WHO-GMP and ISO 9001:2000 certifications, which are essential for market access in these regions. While specific details regarding regulatory filings, approvals, and market access status in these countries are not publicly disclosed, the company's adherence to international quality standards positions it favorably for entry into these markets.

2Emerging Markets

Lyka Labs Limited has demonstrated a commitment to expanding its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's WHO-GMP and ISO 9001:2000 certifications enhance its credibility and facilitate access to these regions. Additionally, the company's export activities, as evidenced by its total export value of $3.4 million USD and 104 shipments across five therapeutic categories, indicate a proactive approach to penetrating diverse markets.

3Geographic Strategy

Lyka Labs Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Lyka Labs Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's adherence to WHO-GMP and ISO 9001:2000 certifications suggests a commitment to quality standards that align with FDA requirements. However, without explicit FDA approvals or registrations, the company's products may face challenges in entering the U.S. market.

2WHO & EU GMP

Lyka Labs Limited's manufacturing facility holds WHO-GMP and ISO 9001:2000 certifications, indicating compliance with international quality standards. While these certifications are recognized globally, including in the European Union, specific EU GMP certificates or EDQM status are not publicly disclosed. Obtaining EU GMP certification would be advantageous for market access within the European Union.

3CDSCO & Indian Regulatory

Lyka Labs Limited's manufacturing facility is licensed by the Central Drugs Standard Control Organisation (CDSCO), as evidenced by its WHO-GMP and ISO 9001:2000 certifications. The company also holds state drug controller approvals and export No Objection Certificates (NOCs), facilitating its export activities. These regulatory approvals underscore the company's compliance with Indian pharmaceutical regulations and its commitment to quality standards.

Lyka Labs Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Lyka Labs Limited operates in a competitive pharmaceutical industry, with numerous companies offering similar products across overlapping therapeutic categories. While specific market share comparisons and head-to-head analyses are not publicly available, the company's export activities, including a total export value of $3.4 million USD and 104 shipments across five therapeutic categories, indicate a proactive approach to market penetration. The lack of a market leader position in any specific category suggests opportunities for growth and increased market share.

2Key Differentiators

Lyka Labs Limited's key differentiators include its commitment to innovation, as evidenced by its state-of-the-art manufacturing facility and adherence to international quality standards. The company's focus on a select range of products, with the top five products accounting for 100% of its export value, indicates a strategic emphasis on quality and reliability. Additionally, the company's proactive approach to export activities demonstrates its commitment to expanding its global footprint.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Lyka Labs Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Lyka Labs Limited has demonstrated a consistent track record in manufacturing and exporting pharmaceutical formulations, with a total export value of $3.4 million USD and 104 shipments across five therapeutic categories. The company's adherence to WHO-GMP and ISO 9001:2000 certifications indicates a commitment to quality and reliability. However, the lack of specific FDA approvals or registrations may impact its ability to supply certain markets, such as the United States.

2Certifications to Verify

Importers should verify the following certifications when considering Lyka Labs Limited as a supplier:

WHO-GMP Certification: Indicates compliance with World Health Organization Good Manufacturing Practices.

ISO 9001:2000 Certification: Demonstrates adherence to international quality management standards.

These certifications can typically be verified through the company's official website or by contacting the company directly.

Due Diligence Checklist

Frequently Asked Questions — Lyka Labs Limited

How many pharmaceutical products does Lyka Labs Limited export from India?

Lyka Labs Limited exports 5 pharmaceutical products across 5 therapeutic categories. The top exports are Vancomycin ($1.4M), Hydrocortisone ($1.1M), Amikacin ($550.0K), Amphotericin ($209.2K), Levamisole ($150.0K). Total export value is $3.4M.

What is Lyka Labs Limited's total pharmaceutical export value?

Lyka Labs Limited's total pharmaceutical export value is $3.4M, based on 104 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Lyka Labs Limited cover?

Lyka Labs Limited exports across 5 therapeutic categories. The largest are Antibiotics (40.4%, 1 products), Corticosteroids (32.7%, 1 products), Advanced Antibiotics (16.3%, 1 products).

Get Full Lyka Labs Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.